PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
June 10, 2021 09:30 ET | PAVmed Inc.
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its...
PAVMEDLOGONEW15OCT2018.png
Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies
May 24, 2021 09:30 ET | PAVmed Inc.
Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) --...
PAVMEDLOGONEW15OCT2018.png
PAVmed Provides Business Update and First Quarter 2021 Financial Results
May 17, 2021 16:00 ET | PAVmed Inc.
Conference call to be held today at 4:30 PM EDT NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product,...
PAVMEDLOGONEW15OCT2018.png
PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results
February 22, 2021 08:18 ET | PAVmed Inc.
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its...
PAVMEDLOGONEW15OCT2018.png
Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
June 15, 2020 09:30 ET | PAVmed Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical...
PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
November 07, 2019 09:30 ET | PAVmed Inc.
Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK,...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on November 21, 2019
November 06, 2019 09:30 ET | PAVmed Inc.
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVMEDLOGONEW15OCT2018.png
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
November 05, 2019 07:00 ET | PAVmed Inc.
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Hold Business Update Conference Call on September 5, 2019
August 07, 2019 09:30 ET | PAVmed Inc.
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVMEDLOGONEW15OCT2018.png
PAVmed to Join Russell Microcap® Index
June 26, 2019 09:30 ET | PAVmed Inc.
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company...